COVID-19 vaccines: Public health experts urge government to release details of adverse event data

Twenty-nine experts from various fields have written a letter noting that the government had stopped sharing any details on Adverse Events Following Immunisation (AEFI) after February 26, 2021. The experts have sought details from the government on the findings of all completed AEFI investigations. The letter said that at least 65 deaths have occurred following vaccination for Covid-19 since the campaign began on January 16. However, the National AEFI Committee’s reports on only two of those deaths have been made public.

Viswanath Pilla
March 17, 2021 / 02:34 PM IST

Representative image: Reuters

A group of experts has expressed concern over the Central government not sharing data on serious Adverse Events Following Immunisation (AEFI) with Covid-19 vaccines, and sought details of all AEFIs as of March 16, as well as the status of investigations into those events.

AEFIs have to be investigated through well-defined procedures for vaccine pharmacovigilance and the reports have to be made available in the public domain to build trust and ensure transparency.  This is especially important for new vaccines such as the Covid vaccines currently being rolled out across the country under emergency-use authorisation.

In a letter, the 29 experts from the fields of public health, ethics, medicine, law, and journalism, who support the immunisation programme, have sought details from the government regarding findings of all completed serious AEFI investigations. In particular, they have sought details of cause of death, by clinical diagnosis; autopsy findings where possible to confirm or revise the clinical diagnosis; causality assessments and the reasoning behind those assessments.

The experts also wanted to know the processes undertaken by various AEFI committees, including whether the WHO guidelines for investigation of AEFIs occurring as a cluster have been strictly followed.

The public health experts noted that the government had stopped sharing any details on AEFIs after February 26, 2021.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The letter was addressed to Health Minister Dr Harsh Vardhan; Drug Controller General of India VG Somani; Niti Aayog Member VK Paul; Department of Biotechnology Secretary Renu Swarup; and NK Arora, Member, National Task Force on Covid-19 and National AEFI Committee.

Moneycontrol has seen a copy of the letter.

In January, the experts had written to the government expressing concern over the lack of information on investigations into deaths following Covid-19 vaccinations in India.

"In our letter dated January 31, 2021, we asked for details of all investigations into deaths and other serious AEFIs, as well as the minutes of AEFI monitoring committees, and details of all AEFI committee members and other experts overseeing the vaccine rollout. We have not received any response," the letter said.

The letter alleged that critical updates to the fact sheets recommended by the CDSCO’s Subject Expert Committee have not been issued, even though they are meant to provide additional guidance and clarify the use of the vaccines in certain persons, such as those with allergies, those who are immunocompromised or using immunosuppressants, or those using blood thinners/anti-coagulants.

The letter also said that there are gaps in AEFI investigations at the local level affecting the quality of evidence submitted to State and National AEFI Committees, which depend on these findings to make causality assessments.

The letter said that at least 65 deaths have occurred following vaccination for Covid-19 since the campaign began on January 16. However, the National AEFI Committee’s reports on only two of those deaths have been made public.

"Media reports indicate that many deaths post vaccination with Covishield, AstraZeneca’s vaccine, which is being manufactured in India by the Serum Institute of India, occurred due to cardiac arrest, cerebral venous thrombosis and stroke," the letter said.

Denmark, Iceland, Norway, Italy, France, Bulgaria, Germany, Luxembourg, Estonia, Lithuania, Latvia and Ireland have paused immunisation with the AstraZeneca vaccine pending investigation of a small number of post-vaccination deaths from intravascular clotting or thromboembolic events, while Austria has suspended the use of certain batches.

The European Medicines Agency and WHO said that the benefits of the AstraZeneca coronavirus vaccine outweighed the risks amid concerns that the shots caused blood clots in some people.

The health experts include Amar Jesani, Editor, Indian Journal of Medical Ethics; Anand Grover, Senior Advocate, Director, Lawyers’ Collective; Dr Babu KV, Public Health Activist, Kannur; Brinelle D’Souza, Co-convenor, Jan Swasthya Abhiyan and faculty member, School of Social Work, Tata Institute of Social Sciences, Mumbai;  Laxmi Murthy, Journalist, Bengaluru; S Srinivasan, LOCOST, Vadodara; Dr SP Kalantri, Physician, Sewagram; Dr Siddhartha Das, Theoretical Physicist, Purnea, Bihar; Dr T Jacob John, Retired Professor and Head, Department of Clinical Virology, Christian Medical College; Malini Aisola, Public Health Professional.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
TAGS: #Business #Companies #coronavirus #Health
first published: Mar 17, 2021 02:09 pm